- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:10 | Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 | 171 | GlobeNewswire (Europe) | Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17, 2025, followed by a webinar on October 22, 2025, providing... ► Artikel lesen | |
| Mi | Evaxion expands AI-Immunology platform with automated vaccine design module | 220 | GlobeNewswire (Europe) | New platform module automates previous manual vaccine design processes, improving quality and dramatically reducing time and resource requirementsAI-Immunology, already superior in vaccine target discovery... ► Artikel lesen | |
| 06.10. | Evaxion A/S - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 03.10. | Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting | 323 | GlobeNewswire (Europe) | New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting The data will be the latest of many additions... ► Artikel lesen | |
| 25.09. | MSD pays up to nearly $600m for Evaxion's mystery vaccine candidate | 32 | Pharmaceutical Technology | ||
| 25.09. | Evaxion Stock Jumps 27% On Merck Out-Licensing Deal | 18 | RTTNews | ||
| 25.09. | Evaxion Out-licenses Vaccine Candidate EVX-B3 To Merck & Co. | 359 | AFX News | KENILWORTH (NJ) (dpa-AFX) - TechBio company Evaxion A/S (EVAX) announced Thursday it has out-licensed its vaccine candidate EVX-B3 to Merck & Co., Inc. or MSD (MRK), as per the option and license... ► Artikel lesen | |
| 25.09. | Evaxion A/S - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| EVAXION Aktie jetzt für 0€ handeln | |||||
| 25.09. | Evaxion out-licenses vaccine candidate EVX-B3 to MSD | 382 | GlobeNewswire (Europe) | MSD exercises its option on vaccine candidate EVX-B3 for a cash payment of $7.5 million, which extend Evaxion's cash runway to first half of 2027 MSD will assume full responsibility for the further... ► Artikel lesen | |
| 25.09. | MSD exercises option on Evaxion's vaccine candidate for $7.5 million | 17 | Investing.com | ||
| 27.08. | Evaxion A/S - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 27.08. | Evaxion to present at several conferences during the second half of 2025 | 361 | GlobeNewswire (Europe) | Evaxion will provide scientific and company updates at numerous conferences in both the US, Europe and Asia during the coming months
COPENHAGEN, Denmark, August 27, 2025 - Evaxion A/S (NASDAQ: EVAX)... ► Artikel lesen | |
| 14.08. | Evaxion Biotech ADS GAAP EPS of -$0.02 | 2 | Seeking Alpha | ||
| 14.08. | Evaxion announces business update and second quarter 2025 financial results | 449 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, August 14, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, provides business update and... ► Artikel lesen | |
| 13.08. | Insights Ahead: Evaxion Biotech's Quarterly Earnings | 1 | Benzinga.com | ||
| 11.08. | Evaxion A/S - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 11.08. | Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025 | 292 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, August 11, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, will provide a business update... ► Artikel lesen | |
| 25.07. | Evaxion A/S - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 25.07. | Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 | 436 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, will be presenting two-year clinical... ► Artikel lesen | |
| 11.07. | Evaxion finalizes €3.5 million debt-to-equity deal with EIB | 3 | Investing.com |
1 2 3 4 Weiter >>
69 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,40 | +0,63 % | Krebsforschung mit Milliarden-Potenzial: So könnten Bayer, Vidac Pharma und BioNTech ins Spiel kommen | Der Onkologie-Markt brummt wie kaum ein anderer. Getrieben von technologischen Quantensprüngen und leider auch steigenden Fallzahlen, entwickelt sich die Krebsbehandlung zum lukrativen Innovationsmotor.... ► Artikel lesen | |
| EVOTEC | 6,786 | +1,31 % | BioNxt Solutions, Bayer, Evotec - Enormes Upside! Schnittstelle von Biotech und Pharma! | Die weltweite Zunahme von Wohlstandserkrankungen wie Diabetes, Adipositas, Multipler Sklerose (MS) und MASH (metabolisch bedingte Fettleber) sorgt für ein enormes Wachstum im Gesundheitssektor. Ebenso... ► Artikel lesen | |
| QIAGEN | 40,955 | +1,20 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| CUREVAC | 4,636 | +0,13 % | CureVac-Aktie im Krisenmodus: Bricht jetzt alles zusammen? Anleger fürchten das Schlimmste!!! | ||
| PAION | 0,017 | -23,21 % | Interne Dokumente des Wirtschaftsministeriums zeigen: So lief der umstrittene Verkauf der Paion AG an chinesische Investoren ab | ||
| AMGEN | 253,90 | +1,58 % | Amgen Launches AmgenNow, Direct-to-patient Program; Available To Repatha Patients | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha or evolucumab. Repatha will be available through AmgenNow at a... ► Artikel lesen | |
| NOVAVAX | 7,526 | +4,98 % | Novavax hands over Nuvaxovid marketing rights to Sanofi in the EU | ||
| STRYKER | 314,60 | +0,19 % | If You Invested $100 In Stryker Stock 20 Years Ago, You Would Have This Much Today | ||
| BIOGEN | 125,85 | -0,32 % | Biogen - BIIB: Leqembi erhält Zulassungen in China & Australien! | Pullback-Setup mit Bullenflagge! Neuausrichtung bei Biogen (BIIB): Alcyone Therapeutics für rund 85 Millionen USD übernommen & Rückzug aus AAV-basierten Gentherapieprojekten! Biogen (BIIB) - ISIN US09062X1037... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 59,50 | -5,56 % | Citizens bestätigt "Market Outperform"-Rating für CRISPR Therapeutics | ||
| CORE ONE LABS | 0,079 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| OCUGEN | 1,380 | -5,99 % | Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25%... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 22,945 | +1,30 % | UBS bestätigt Kaufempfehlung für Summit Therapeutics vor ESMO-Daten | ||
| RECURSION PHARMACEUTICALS | 5,525 | +4,15 % | RECURSION PHARMACEUTICALS INC zündet den Turbo jetzt! | ||
| GUBRA | 54,40 | -4,98 % | Pila Pharma AB: Pila Pharma Enters Into Agreement With The Cro Gubra On Preclinical Trials Of Xen-d0501 In Obesity | PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs for treatment of obesity and diabetes based on TRPV1 inhibition, informs investors and others with interest... ► Artikel lesen |
EVAXION A/S ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 6,260 Euro und damit +7,01 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EVAXION A/S ADR finden Sie auf Wallstreet Online.